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ABSTRACT Patients with lung disease caused by Mycobacterium abscessus subsp.
abscessus (here M. abscessus) typically have poor treatment outcomes. Although clo-
fazimine (CFZ) has been increasingly used in the treatment of M. abscessus lung dis-
ease in clinical practice, there are no reported data on its effectiveness for this dis-
ease. This study sought to evaluate the clinical efﬁcacy of a CFZ-containing regimen
for the treatment of M. abscessus lung disease. We performed a retrospective review
of the medical records of 42 patients with M. abscessus lung disease who were treated
with CFZ-containing regimens between November 2013 and January 2015. CFZ was ad-
ministered in combination with other antibiotics as an initial antibiotic regimen in 15
(36%) patients (initial treatment group), and it was added to an existing antibiotic regi-
men for refractory M. abscessus lung disease in 27 (64%) patients (salvage treatment
group). Overall, there was an 81% treatment response rate based on symptoms and a
31% response rate based on radiographic ﬁndings. Conversion to culture-negative spu-
tum samples was achieved in 10 (24%) patients after CFZ-containing antibiotic treat-
ment, and during treatment, there were signiﬁcant decreases in the positivity of semi-
quantitative sputum cultures for acid-fast bacilli in both the initial (P  0.018) and
salvage (P  0.001) treatment groups. Our study suggests that CFZ-containing regimens
may improve treatment outcomes in patients with M. abscessus lung disease and that a
prospective evaluation of CFZ in M. abscessus lung disease is warranted.
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The prevalence of pulmonary disease caused by nontuberculous mycobacteria(NTM) is increasing worldwide (1, 2). The Mycobacterium abscessus complex is the
most important cause of pulmonary infections by rapidly growing mycobacteria in
patients with chronic lung diseases such as bronchiectasis and cystic ﬁbrosis (3, 4).
Currently, the M. abscessus complex can be divided into three subspecies: M. abscessus
subsp. abscessus (here M. abscessus), M. abscessus subsp. massiliense (here M. massil-
iense), and M. abscessus subsp. bolletii (here M. bolletii) (5, 6). Among these three
subspecies, M. abscessus is the most common pathogen (45 to 65%), followed by M.
massiliense (20 to 55%) and M. bolletii (1 to 18%) (7).
M. abscessus is highly drug resistant. Guidelines from the American Thoracic Society
and the Infectious Diseases Society of America recommend macrolide-based antibiotic
therapy combined with intravenous amikacin (AMK) and either cefoxitin or imipenem,
based on drug susceptibility testing (DST) (3). However, given the level of effectiveness
Received 22 September 2016 Returned for
modiﬁcation 8 January 2017 Accepted 20
March 2017
Accepted manuscript posted online 27
March 2017
Citation Yang B, Jhun BW, Moon SM, Lee H,
Park HY, Jeon K, Kim DH, Kim S-Y, Shin SJ, Daley
CL, Koh W-J. 2017. Clofazimine-containing
regimen for the treatment ofMycobacterium
abscessus lung disease. Antimicrob Agents
Chemother 61:e02052-16. https://doi.org/10
.1128/AAC.02052-16.
Copyright © 2017 American Society for
Microbiology. All Rights Reserved.
Address correspondence to Won-Jung Koh,
wjkoh@skku.edu.
B.Y. and B.W.J. contributed equally to this work.
CLINICAL THERAPEUTICS
crossm
June 2017 Volume 61 Issue 6 e02052-16 aac.asm.org 1Antimicrobial Agents and Chemotherapy
of current antibiotic options (3), M. abscessus lung disease is considered a chronic,
incurable infection for most patients, and the sputum culture conversion rates are low
(8–12).
Clofazimine (CFZ) is a fat-soluble riminophenazine dye that was developed in the
1950s, mainly for use in the treatment of leprosy (13). This antimicrobial was recently
introduced for the treatment of multidrug-resistant or extensively drug-resistant tuber-
culosis (14–17). Several reports have also reported the clinical efﬁcacy of CFZ in the
treatment of Mycobacterium avium complex lung disease (18–22); however, the results
are inconsistent. Regarding M. abscessus infection, in vitro DST studies demonstrated a
low MIC of CFZ and in vitro synergy between CFZ and other antibiotics, such as
clarithromycin (CLR), AMK, or tigecycline (23–28). The antimycobacterial activity of CFZ
against M. abscessus was also demonstrated in vivo with Drosophila melanogaster and
mouse models of infection (29, 30).
CFZ has been increasingly used in the treatment of M. abscessus lung disease in
clinical practice (31, 32). Moreover, the U.S. Cystic Fibrosis Foundation and the Euro-
pean Cystic Fibrosis Society recently recommended that the continuation phase of M.
abscessus lung disease treatment should include a daily oral macrolide, inhaled ami-
kacin, and two or three additional oral antibiotics, including CFZ (4). However, there are
no reported data concerning the effect of CFZ on M. abscessus lung disease. Therefore,
the purpose of this study was to evaluate the clinical efﬁcacy and safety of a CFZ-
containing regimen for the treatment of M. abscessus lung disease.
RESULTS
Patient characteristics. The characteristics of the 42 patients withM. abscessus lung
disease are shown in Table 1. The median patient age was 60 years, and most patients
(79%) were female. Most patients (n 36; 86%) had the nodular bronchiectatic form of
M. abscessus lung disease. A total of 29 patients (69%) had positive acid-fast bacillus
(AFB) sputum smears at the time of initiation of CFZ-containing antibiotic therapy.
CFZ was part of the initial treatment in 15 (36%) patients and was added as a salvage
drug in 27 (64%) patients who had failed sputum culture conversion despite a median
of 113.6 weeks (interquartile range [IQR], 51.2 to 232.4 weeks) of treatment with other
antibiotics.
TABLE 1 Clinical characteristics of patients receiving clofazimine-containing antibiotic
therapya
Clinical characteristic Value (n  42)
Median age (yr) (IQR) 60 (53–69)
No. (%) of female patients 33 (79)
Median body mass index (kg/m2) (IQR) 20 (18–22)
No. (%) of nonsmokers 33 (79)
No. (%) of patients with underlying lung disease
Bronchiectasis 36 (86)
Previous tuberculosis 11 (26)
Obstructive pulmonary disease 3 (7)
Chronic pulmonary aspergillosis 5 (12)
Laboratory ﬁndings
Median ESR level (mm/h) (IQR) 47 (24–79)
Median CRP level (mg/dl) (IQR) 0.57 (0.11–1.47)
No. (%) of patients with radiographic type
Nodular bronchiectatic form 36 (86)
With cavity 19
Without cavity 17
Fibrocavitary form 6 (14)
No. (%) of patients with positive sputum AFB smear 29 (69)
No. (%) of patients in initial treatment group 15 (36)
No. (%) of patients in salvage treatment group 27 (64)
aAbbreviations: ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; AFB, acid-fast bacillus.
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For the 15 patients from the initial treatment group, 13 (87%) of the M. abscessus
isolates had inducible resistance to CLR, and 2 (13%) were susceptible to CLR. For the
27 patients in the salvage treatment group, 23 (85%) of the M. abscessus isolates had
inducible resistance to CLR, and 4 (15%) were resistant to CLR when the administration
of CFZ began.
Treatment. The antibiotic regimens for the 42 patients are shown in Table 2. All
patients received oral CFZ and a macrolide such as azithromycin (AZM) (n  41) or CLR
(n  1). The median treatment duration of oral CFZ was 48.0 weeks (IQR, 24.8 to 48.0
weeks). All 15 patients in the initial treatment group received initial 4-week intravenous
combination antibiotic therapy.
All 27 patients in the salvage treatment group had persistent positive cultures after
at least 6 months of previous antibiotic therapy for M. abscessus lung disease, which
had consisted of an oral macrolide (CLR [n  17; 63%] or AZM [n  19; 70%]), oral
ﬂuoroquinolones (ciproﬂoxacin [n  5; 12%] or moxiﬂoxacin [n  4; 10%]), and
intravenous antibiotics, including AMK (n  27; 100%), cefoxitin (n  17; 63%), or
imipenem (n  10; 37%). In the salvage treatment group, 13 patients received 4 weeks
of combination intravenous antibiotic treatment after rehospitalization, which included
amikacin and cefoxitin (or imipenem) in addition to CFZ; the 14 remaining patients
received CFZ in addition to the continuing oral regimen, such as oral macrolides
(azithromycin or clarithromycin), in outpatient settings (Table 2).
Surgical resection, or lobectomy, was performed on three patients (one in the initial
treatment group and two in the salvage treatment group) during the course of
antibiotic treatment.
Treatment responses after 12 months of a CFZ-containing regimen. As shown
in Table 3, there was an overall 81% treatment response rate based on symptoms and
a 31% response rate based on radiographic ﬁndings. Although the level of symptomatic
improvement appeared higher in the initial treatment group than in the salvage
treatment group, the difference was not statistically signiﬁcant (93% [14/15] versus 74%
[20/27]; P  0.222). Initial and 12-month follow-up high-resolution computed tomog-
raphy (HRCT) images (n  33) or chest radiographs (n  9) were available for all
patients. Radiologic improvement was notably greater in the initial treatment group
than in the salvage treatment group (53% [8/15] versus 19% [5/27]; P  0.020).
TABLE 2 Antibiotics administered to the initial and salvage treatment groupsa
Drug
No. of patients receiving
treatment (%) (n  42)
Median duration of
treatment (wk) (IQR)
Clofazimine 42 (100) 48.0 (24.8–48.0)
Amikacin 28 (67)a 4.0 (3.7–4.0)
Cefoxitin 19 (45)a 3.3 (1.1–4.0)
Imipenem 9 (21)a 2.7 (1.4–3.6)
Macrolide 42 (100) 52.1 (44.5–52.1)
aAll 15 patients in the initial treatment group received initial 4-week intravenous combination antibiotic
therapy including amikacin and cefoxitin (or imipenem). Of the 27 patients in the salvage treatment group,
13 patients received 4-week combination intravenous antibiotic treatment after rehospitalization when
clofazimine was added, and 14 patients received clofazimine in addition to the continuing oral regimen in
outpatient settings.
TABLE 3 Treatment responses after 12 months of treatment with a clofazimine-containing
regimen
Parameter Value (n  42)
No. (%) of patients with symptomatic improvement 34 (81)
No. (%) of patients with radiologic improvement 13 (31)
Microbiologic improvement
No. (%) of patients with sputum culture conversion 10 (24)a
Median time to negative culture conversion (wk) (IQR) 5.0 (4.6–28.9)
aSputum negative culture conversion was achieved in 40% (6/15) of patients in the initial treatment group
and in 15% (4/27) of patients in the salvage treatment group.
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Sputum negative culture conversion was achieved in 10 (24%) patients after treat-
ment with a CFZ-containing antibiotic (Fig. 1). The culture conversion rate was higher
in the initial treatment group than that in the salvage treatment group, although the
difference was not statistically signiﬁcant (40% [6/15] versus 15% [4/27]; P  0.128).
Within the salvage treatment group, the culture conversion rates did not differ between
patients who started CFZ together with intravenous antibiotic treatment (2/13; 15%)
and those who received CFZ in addition to the continuing oral regimen (2/14; 14%)
(P  0.936). Figure 2 shows the results of serial testing (every 3 months) for sputum
culture positivity, using solid media, after patients started a CFZ-containing regimen.
During antibiotic treatment, sputum culture positivity trended lower in both the initial
and salvage treatment groups, with statistically signiﬁcant decreases being detected
(P  0.018 for the initial treatment group and P  0.001 for the salvage treatment
group).
Adverse effects associated with CFZ. During the treatment period, 23 (55%)
patients experienced adverse effects from CFZ, resulting in either the discontinuation
of the drug in 18 patients after 24.4 weeks (IQR, 17.2 to 40.8 weeks) of CFZ treatment
or a dose reduction to 50 mg/day in 5 patients after 26.0 weeks (IQR, 17.7 to 36.2 weeks)
of CFZ treatment (Table 4). Gastrointestinal disturbance was the most common cause
of discontinuation (11 patients), and ﬁve patients discontinued CFZ due to reddish-
brown skin discoloration.
FIG 1 Cumulative sputum culture conversion rates after patients started a clofazimine-containing
regimen.
FIG 2 Serial changes in semiquantitative AFB sputum culture positivity on solid media after patients
started a clofazimine-containing regimen. Vertical bars indicate the interquartile ranges.
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DISCUSSION
In this study, we evaluated the clinical, radiologic, and microbiological responses of
42 patients with M. abscessus lung disease treated with CFZ-containing regimens. The
most noticeable ﬁnding was that CFZ-containing regimens were moderately effective
in treating M. abscessus lung disease. AFB culture conversion was achieved in 10 (24%)
of the 42 study patients and in 6 (40%) of the 15 patients initially treated with CFZ.
CFZ is primarily used to treat leprosy due to its lipophilicity in the skin and
anti-inﬂammatory properties (13), but it has recently been applied for the treatment of
drug-resistant tuberculosis (14–17). In mouse models of drug-susceptible and drug-
resistant tuberculosis, lung culture conversion and relapse-free cure were obtained
much earlier in mice treated with the CFZ-supplemented regimen than in those treated
with the control standard regimen (33, 34). Moreover, previous studies reported that for
treatment of mycobacterial diseases, CFZ has many advantageous characteristics such
as a long half-life, slow metabolic elimination, the ability to achieve high concentrations
in macrophages, rapid localization within phagocytes, and low cost (35–37). In addition,
recent in vitro studies have shown that CFZ has signiﬁcant synergistic activity when it
is combined with AMK or CLR (23–28). Notably, a recent experimental study reported
that CFZ prevented the regrowth of the M. abscessus type strain exposed to AMK and
CLR (28). Although the experimental studies cited above suggest a potential role for
CFZ in the treatment of NTM lung disease, several clinical studies evaluating the efﬁcacy
of CFZ for the treatment of M. avium complex lung disease reported inconsistent
response rates (18–22), and clinical data on the outcomes of patients with M. abscessus
lung disease treated with CFZ are extremely limited (31).
In our previous reports, sputum culture conversion rates ranged from 25% to 34%
after 12 months of antibiotic treatment that did not include CFZ (8, 12). In another two
studies in which the subspecies of the M. abscessus complex isolate causing M.
abscessus lung disease was also identiﬁed, sputum culture conversion rates were 26 to
42% after long-term antibiotic therapy without CFZ (9, 11). In the present study, sputum
culture conversion was achieved in 40% (6/15) of patients after antibiotic treatment
that included CFZ from the start of the antibiotic regimen. Additionally, the sputum
culture conversion rate seemed to be slightly higher (40%) when CFZ was used in
combination with other antibiotics from the beginning of the treatment than the rates
(25 to 34%) obtained in our previous studies in which we used almost the same
antibiotic regimens and treatment duration, except for the exclusion of CFZ (8, 12);
however, interpretations of the differing rates are difﬁcult due to the small study
population.
In the salvage treatment group, in which CFZ was added to the existing failing
regimens, the sputum culture conversion rate was only 15% (15/27). However, the
salvage treatment group was anticipated to be a more difﬁcult group to treat in view
of their previous and unsuccessful long-term antibiotic therapy. In addition, whereas
13% (2/12) of M. abscessus isolates were susceptible to CLR in the initial treatment
group, no CLR-susceptible M. abscessus isolates were found in the salvage treatment
group. In the present study, the salvage treatment group was deﬁned as patients who
had refractory M. abscessus lung disease, as indicated by persistent positive cultures
after at least 6 months of antibiotic therapy. Because most patients with CLR-susceptibleM.
TABLE 4 Adverse effects associated with clofazimine
Adverse effect
No. (%) of patients
Discontinuation
(n  18)
Dose reduction
(n  5) Total (n  23)
Gastrointestinal disturbance 11 (61) 1 (20) 12 (52)
Skin color change 5 (28) 4 (80) 9 (39)
Dizziness 1 (6) 0 (0) 1 (4)
Others 1 (6)a 0 (0) 1 (4)
aThis patient discontinued all antibiotics for M. abscessus lung disease, including clofazimine, after
admittance to the intensive care unit due to severe pneumonia and sepsis.
Clofazimine for Treatment of M. abscessus Lung Disease Antimicrobial Agents and Chemotherapy
June 2017 Volume 61 Issue 6 e02052-16 aac.asm.org 5
abscessus lung disease were successfully treated with macrolide-containing antibiotic reg-
imens (12), the high CLR resistance rate in the salvage treatment group could be expected.
However, this study demonstrated a signiﬁcant decrease in the positivity of semiquantita-
tive sputum cultures for AFB over the course of treatment with CFZ in both the initial
treatment and salvage treatment groups, suggesting that CFZ-containing regimens can
help to decrease the mycobacterial burden. Semiquantitative AFB culture positivity is likely
to reﬂect disease burden and was used to assess microbiological responses to the treat-
ment of NTM lung disease in some recently reported studies (38–40).
Given thatM. abscessus lung disease is regarded as a chronic, incurable infection and
that there are limited antibiotic options, improvement in the health-related quality of
life is a reasonable treatment goal, especially in refractory cases (32). Therefore, in these
contexts, administering an additional available oral agent, such as CFZ, which does not
require the placement of an intravenous catheter, is a treatment strategy worth
considering. Unfortunately, 43% (18/42) of our study patients discontinued CFZ during
the course of treatment due to adverse effects such as gastrointestinal disturbance or
skin discoloration. In recent studies, the two most commonly reported adverse effects
of CFZ or CFZ-containing regimens were gastrointestinal disturbance and skin color
change, which were reported in 14 to 89% of cases treated with CFZ for drug-resistant
tuberculosis (41–43). In our study, patients who experienced gastrointestinal distur-
bances due to CFZ had nausea, vomiting, and abdominal discomfort, but there were no
associated life-threatening gastrointestinal complications. Patients who experienced
skin color changes did not have recurrent problems once the CFZ dose was decreased
or discontinued. Although 43% of patients in our study discontinued CFZ due to side
effects, the drug was relatively well tolerated, with no severe adverse effects.
This study had several limitations. First, this retrospective study included a relatively
small sample of patients, and as it was not a controlled clinical trial, we did not have
a control group for which CFZ therapy was omitted. Second, because we evaluated the
treatment responses after 12 months of CFZ administration, long-term clinical and
radiologic responses or maintenance of the conversion rate could not be evaluated.
Third, because of its retrospective nature, data were not collected in a standardized
fashion, especially for clinical symptoms and HRCT ﬁndings.
In conclusion, we evaluated the clinical, radiologic, and microbiological responses of
42 patients treated with CFZ-containing regimens for M. abscessus lung disease and
found that these regimens were moderately effective. However, further evaluation of
the clinical efﬁcacy and adverse effects of long-term CFZ-containing regimens in
patients with M. abscessus lung disease is needed.
MATERIALS AND METHODS
Study population. Consecutive patients with M. abscessus lung disease who received CFZ between
November 2013 and January 2015 were identiﬁed from the NTM Registry of Samsung Medical Center (a
1,979-bed referral hospital in Seoul, South Korea), and their medical records were reviewed. CFZ has been
available for the treatment of M. abscessus lung disease at our institution since November 2013. This
retrospective study was approved by the Institutional Review Board (IRB) of Samsung Medical Center (IRB
approval no. 2016-05-018). The patient information was anonymized and deidentiﬁed prior to analysis,
and therefore, informed consent was waived.
A total of 42 patients with M. abscessus lung disease treated with a CFZ-containing regimen were
identiﬁed. All of these patients fulﬁlled the diagnostic criteria for NTM lung disease (3), and they were
divided into two groups based on the timing of the administration of CFZ. In the “initial treatment
group,” consisting of 15 patients (36%), CFZ had been administered from the start of the antibiotic
regimen in conjunction with other antibiotics. In the “salvage treatment group,” CFZ had been added to
the existing regimen for 27 patients (64%) who had refractory M. abscessus lung disease, as indicated by
persistent positive cultures after at least 6 months of antibiotic therapy. None of the patients had
received CFZ prior to this study.
Radiographic and microbiological examination. Chest radiography and HRCT images were avail-
able at the time of CFZ-containing antibiotic treatment for all patients. The ﬁbrocavitary form (previously
called the upper lobe cavitary form) is deﬁned by the presence of cavitary opacities, mainly in the upper
lobes. The nodular bronchiectatic form is deﬁned by the presence of bronchiectasis and multiple nodules
upon chest HRCT, regardless of the presence of small cavities in the lungs (44, 45).
Sputum AFB smears and cultures were obtained by using standard methods (46). All clinical samples
were cultured both on 3% Ogawa solid medium (Shinyang, Seoul, South Korea) and in liquid broth
medium in mycobacterial growth indicator tubes (MGITs) (Becton-Dickinson and Co., Sparks, MD, USA).
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During the study period, NTM species were identiﬁed by using a reverse blot hybridization assay of the
rpoB gene (47), followed by multilocus sequencing analysis of the rrs, hsp65, and rpoB genes (48). DST was
performed by using the broth microdilution method (49). The MIC of CLR was determined on days 3 and
14 after incubation. Clinical isolates were considered susceptible (MIC of 2 g/ml at days 3 and 14),
resistant (MIC of 8 g/ml at day 3), or inducibly resistant (susceptible at day 3 but resistant at day 14)
to CLR (49). MICs for CFZ were not determined in this study period.
Antibiotic therapy. The initial treatment group was hospitalized for 4 weeks and received multiple
antibiotics, including oral CFZ (100 mg/day) and a macrolide (AZM at 250 mg/day or CLR at 1,000
mg/day), along with an initial 4-week course of intravenous AMK (15 mg/kg of body weight/day) and
cefoxitin (200 mg/kg/day; maximum of 12 g/day). Imipenem (750 mg three times per day) was
substituted in the event of an adverse reaction to cefoxitin, such as leukopenia. After discharge, the oral
regimen, including CFZ and a macrolide, was continued. If adverse effects to CFZ occurred, the dosage
was reduced or discontinued. In the salvage treatment group, CFZ was added to the existing oral
regimen in the outpatient setting or administered after rehospitalization for combination intravenous
antibiotic treatment.
Evaluation of treatment response. Twelve months after the start of the CFZ-containing regimen,
clinical, radiographic, and microbiological responses were evaluated. Symptomatic responses were
determined by the attending physician. The physician’s subjective assessment of changes in respiratory
condition was recorded 12 months after antibiotic treatment (50). Clinical responses were evaluated by
retrospective medical record evaluation. Radiographic responses were evaluated by comparing the initial
and follow-up HRCT images. When a follow-up HRCT image was not available, a chest radiograph was
used instead. The radiographic images were reviewed by three of the authors (B.Y., S.M.M., and W.-J.K.),
and a consensus was obtained for classifying the radiographic ﬁndings as “improved,” “unchanged,” or
“worse.” Sputum examinations were performed at 3-month intervals during treatment. Sputum conver-
sion was deﬁned as three consecutive negative cultures, and the time of conversion was deﬁned as the
date of the ﬁrst negative culture (8).
Statistical analysis. All data are presented as medians and IQRs for continuous variables and as
numbers (percentages) for categorical variables. Data were compared by using the Mann-Whitney U test
for continuous variables and the Pearson 2 test or Fisher’s exact test for categorical variables. A
two-sided P value of 0.05 was considered statistically signiﬁcant for all analyses. All analyses were
performed by using SPSS statistical software (SPSS version 23; IBM, Armonk, NY). Serial changes in AFB
culture positivity were analyzed with generalized estimating equations using SAS version 9.4 (SAS
Institute, Cary, NC).
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